SCHEMBL19499403

SCHEMBL19499403

O=C1/C(=C/c2ccc(-c3ccccc3)cc2)Oc2ccccc21

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 6/20 0.81
MAOA P21397 2/20 0.72
MAOB P27338 2/20 0.72
HDAC3 O15379 2/20 0.72
HDAC4 P56524 2/20 0.72
HDAC1 Q13547 2/20 0.72
HDAC7 Q8WUI4 2/20 0.72
HDAC2 Q92769 2/20 0.72
HDAC10 Q969S8 2/20 0.72
HDAC11 Q96DB2 2/20 0.72
HDAC8 Q9BY41 2/20 0.72
HDAC6 Q9UBN7 2/20 0.72
HDAC9 Q9UKV0 2/20 0.72
HDAC5 Q9UQL6 2/20 0.72
ELANE P08246 7/20 0.71
ACHE P22303 2/20 0.67
CISD1 Q9NZ45 1/20 0.67
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
RECQL P46063 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19499394 0.92 STK17B (0.89) STK17BMAOAMAOBHDAC3HDAC4
SCHEMBL19462733 0.92 STK17B (0.89) STK17BMAOAMAOBHDAC3HDAC4
(Z)-Aurone SCHEMBL13971324 0.90 STK17B (1.00) STK17BMAOAMAOBHDAC3HDAC4
(Z)-Aurone SCHEMBL305101 0.90 STK17B (1.00) STK17BMAOAMAOBHDAC3HDAC4
(Z)-Aurone SCHEMBL31266594 0.90 STK17B (1.00) STK17BMAOAMAOBHDAC3HDAC4
(Z)-Aurone SCHEMBL305100 0.90 STK17B (1.00) STK17BMAOAMAOBHDAC3HDAC4
(Z)-Aurone SCHEMBL29935711 0.90 STK17B (1.00) STK17BMAOAMAOBHDAC3HDAC4
SCHEMBL19462962 0.84 STK17B (1.00) STK17BMAOAMAOBHDAC3HDAC4
SCHEMBL21082587 0.84 STK17B (0.76) STK17BMAOAMAOBHDAC3HDAC4
SCHEMBL21046422 0.84 STK17B (1.00) STK17BMAOAMAOBHDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210053933-A1 THERAPEUTIC AURONES Middle Tennessee State University (US) 2021-02-25 US disclosed
US-20200399238-A1 THERAPEUTIC AURONES Middle Tennessee State University (US) 2020-12-24 US disclosed
WO-2020223439-A1 AURONES AND METHODS OF USING AURONES TO TREAT TUBERCULOSIS Middle Tennessee State University (US) 2020-11-05 WO disclosed
US-20190169151-A1 THERAPEUTIC AURONES Middle Tennessee State University (US) 2019-06-06 US disclosed
WO-2017180644-A1 THERAPEUTIC AURONES Middle Tennessee State University (US) 2017-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399238-A1 THERAPEUTIC AURONES AURKA, PIGS, PRF1 STK17B 1615/4885MAOA 3636/4885MAOB 3505/4885
US-20210053933-A1 THERAPEUTIC AURONES AURKA, PIGS, PRF1 STK17B 1615/4885MAOA 3636/4885MAOB 3505/4885
US-20190169151-A1 THERAPEUTIC AURONES AURKA, PIGS, PRF1 STK17B 1615/4885MAOA 3636/4885MAOB 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.